Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

Core Insights - BridgeBio Pharma, Inc. (NASDAQ:BBIO) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - Truist analyst Danielle Brill raised the price target for BBIO to $95 from $86, maintaining a Buy rating, citing a 35% increase in Q4 Attruby sales to $146 million [2] - Morgan Stanley analyst Sean Laaman increased the price target for BBIO to $98 from $96, reiterating an Overweight rating after the Q4 report [3] - BridgeBio reported Q4 EPS of ($1.00), missing consensus estimates of (67 cents), but revenue of $154.18 million exceeded the $149.07 million consensus [4] - CEO Neil Kumar highlighted the company's progress, noting three successful Phase 3 readouts in a short period and expressing optimism for six approved products as the company approaches its first decade [4] Financial Performance - Q4 revenue reached $154.18 million, surpassing the consensus estimate of $149.07 million [4] - Q4 Attruby sales were reported at $146 million, reflecting a 35% increase from Q3 [2] - The company reported a Q4 EPS of ($1.00), which was below the consensus estimate of (67 cents) [4] Analyst Ratings - Truist's price target for BBIO is now $95, up from $86, with a Buy rating maintained [2] - Morgan Stanley's price target for BBIO is now $98, increased from $96, with an Overweight rating reiterated [3]